Results 41 to 50 of about 1,091,220 (265)

Early Impact of Childhood Opportunity on Neurocognitive Outcomes in Sickle Cell Disease

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Neurocognitive impairment is a well‐recognized complication of sickle cell disease (SCD) that begins early in childhood and persists across development. While cerebrovascular injury contributes substantially to risk, neurocognitive deficits are also observed in children without overt or silent cerebral infarctions, suggesting ...
Julia E. LaMotte, Hannah Koch, Olivia A. Coughlin, Jillian R. Bouck, Allie Carter, Seethal A. Jacob   +5 more
wiley   +1 more source

Advances in cancer genetics [PDF]

Clinical Medicine, 2009
At the time that I entered the field of clinical genetics in the early 1980s there was an explosion of gene identification leading to a rapid improvement in our ability to diagnose genetic disease and to offer screening and prenatal diagnosis.
openaire   +2 more sources

Psychosocial Functioning After Pediatric Bone Sarcoma: Generic and Survivor‐Specific Outcomes in Adolescent and Young Adult Patients

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Pediatric bone sarcoma patients and survivors may experience psychosocial challenges related to childhood cancer after their intensive, body‐altering treatment. This cross‐sectional study aimed to evaluate generic and survivor‐specific psychosocial outcomes in a national cohort of pediatric bone sarcoma patients and survivors, and ...
Hinke van der Hoek, Heleen Maurice‐Stam, Laura R. Beek, Jennifer van Dijk, Marjolein E. M. Langemeijer, Relinde W. Slooff‐Lentink, Alied M. van der Aa‐van Delden, Anne Westerweel, Marloes van Gorp, Hendrik W. B. Schreuder, Lianne M. Haveman, W. Peter Bekkering, Leonie G. Tigelaar, Johannes H. M. Merks, Martha A. Grootenhuis   +14 more
wiley   +1 more source

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko, Holger N. Lode, Alberto Garaventa, Carla Manzitti, Roberto Luksch, Dominique Valteau‐Couanet, Marion Gambart, John Anderson, Juliet Gray, Adela Canete, Lucas Moreno, Aleksandra Wieczorek, Cormac Owens, Shifra Ash, Isaac Yaniv, Genevieve Laureys, Hans Loibner, Katarzyna Śladowska, Ruth Ladenstein, Paweł Kawalec   +19 more
wiley   +1 more source

An [Imperfect] Case for Dyadic Research in Pediatric Psychosocial Oncology

Pediatric Blood &Cancer, EarlyView.
Stephanie M. Nanos, Lindsay A. Jibb, Gary Rodin   +2 more
wiley   +1 more source

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol, Arlene Naranjo, Lulu Chen, Rajen Mody, Steven G. DuBois, Rochelle Bagatell, Navin Pinto   +6 more
wiley   +1 more source

Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survival after relapse in pediatric acute myeloid leukemia (AML) remains poor, highlighting the critical importance of identifying prognostic factors to guide optimal relapse management. Methods We investigated the prognostic impact of multiparameter flow cytometry (MFC) measurable residual disease (MRD) in 188 patients with first ...
Camilla Poulsen, Kristian Juul Sandahl, Lene Karlsson, Jonas Abrahamsson, Nira Arad‐Cohen, Daniel Cheuk, Barbara De Moerloose, Linda Fogelstrand, Jose Maria Fernandez Navarro, Bianca F. Goemans, Kirsi Jahnukainen, Gertjan Kaspers, Zhanna Kovalova, Monica Cheng Munthe‐Kaas, Ulrika Norén‐Nyström, Josefine Palle, Ramune Pasauliene, Cornelis Jan Pronk, Kadri Saks, Anne Tierens, Henrik Hasle, Kristian Løvvik Juul‐Dam   +21 more
wiley   +1 more source

More competent informal caregivers reduce advanced cancer patients' unplanned healthcare use and costs

Cancer Medicine
Background Patients with metastatic cancer experience high healthcare use and costs, most of which are unplanned. We aimed to assess whether patients with more competent informal caregivers have lower unplanned healthcare use and costs.
Louisa Camille Poco, Chetna Malhotra
doaj   +1 more source

Immune checkpoint inhibitor therapy for advanced HPV-related penile squamous cell carcinoma: a rare case report

Frontiers in Oncology
BackgroundHuman papillomavirus type 16 (HPV-16)-associated penile squamous cell carcinoma (PSCC) poses considerable therapeutic challenges, especially in its advanced stages.
Zhen-Kun Pan, Meng-Hua Wu, Hua Shi, Jin-Sheng Ye   +3 more
doaj   +1 more source

Advances in Cancer Pain [PDF]

Archives of Neurology, 1999
Advances in cancer pain research and management are an example of the advances that have occurred within the field of neuro-oncology, the medical discipline that includes the diagnosis and treatment of primary central nervous system neoplasms, metastatic and nonmetastatic neurological complications of cancer originating outside the nervous system, and ...
openaire   +2 more sources